Flutamide therapy for advanced prostatic cancer: a phase II study.
A non-steroidal antiandrogen (flutamide) was used to treat 17 patients with advanced prostatic cancer. Twelve of 14 patients who had already failed to respond to conventional hormone therapy were dead within 12 months of starting flutamide therapy and there was a high incidence of side effects. Of three patients who had not received prior hormone therapy, two showed an early partial response and one showed no evidence of response to therapy.
D000368:Aged; D000813:Anilides / Q000627:therapeutic use*; D002369:Castration; D003131:Combined Modality Therapy; D004054:Diethylstilbestrol / Q000627:therapeutic use; D004341:Drug Evaluation; D005485:Flutamide / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000601:surgery; D013997:Time Factors
D000813:Anilides; D004054:Diethylstilbestrol; D005485:Flutamide